Castration-Resistant Prostate Cancer

The FDA announced several regulatory actions the past few weeks.

SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

A randomized phase 3 trial that assessed rucaparib for certain men with advanced prostate cancer met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

The FDA granted priority review to olaparib as part of combination therapy treatment of metastatic castration-resistant prostate cancer.

The FDA approved lutetium Lu 177 vipivotide tetraxetan for treatment of certain men with advanced prostate cancer.

Healio spoke with Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, about a study evaluating the use of a chimeric antigen receptor T-cell therapy in a subgroup of patients with prostate cancer.

SAN FRANCISCO — Bavdegalutamide demonstrated clinical activity among heavily pretreated men with metastatic castration-resistant prostate cancer who received novel hormonal agents, according to study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Continued enzalutamide, after progression on the drug, in combination with docetaxel significantly extended PFS compared with placebo and docetaxel among men with metastatic castration-resistant prostate cancer, study results showed.

SAN FRANCISCO  — The addition of olaparib to abiraterone acetate significantly extended radiographic PFS as first-line treatment for metastatic castration-resistant prostate cancer, according to an interim analysis of the randomized phase 3 PROpel study.

The addition of darolutamide to docetaxel and androgen deprivation therapy significantly prolonged OS among men with metastatic hormone-sensitive prostate cancer, according to topline results of the randomized phase 3 ARASENS trial.